Cipla Limited has informed the Exchange about General Updates
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla Limited has informed the stock exchanges that its wholly owned US subsidiary, Cipla USA Inc., has decided to recall all unexpired batches of Lanreotide Injection following discussions with Pharmathen International S.A. This recall will result in a temporary shortage of supply in the US market. The disclosure is being made under SEBI Listing Regulations and follows earlier intimations on 7th January, 14th January, and 21st February 2026. Lanreotide is a drug typically used to treat conditions such as acromegaly and neuroendocrine tumors. The recall signals an ongoing issue with this product line that has been building over the past couple of months.
The voluntary recall and resulting supply gap may lead to short-term revenue impact from the affected product in the US market, and could also involve recall-related costs. Investors should watch for further updates on the financial impact and timeline for restoring supply.